PriceTargets.com logo

FibroGen - FGEN Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $250.00
  • Forecasted Upside: 4,744.96%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$5.16 As of 06/18/2025 05:00 PM ET
▼ -0.72 (-12.24%)

This chart shows the closing price for FGEN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New FibroGen Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for FGEN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for FGEN

Analyst Price Target is $250.00
▲ +4,744.96% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for FibroGen in the last 3 months. The average price target is $250.00, with a high forecast of $250.00 and a low forecast of $250.00. The average price target represents a 4,744.96% upside from the last price of $5.16.

This chart shows the closing price for FGEN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 2 polled investment analysts is to moderate buy stock in FibroGen. This rating has held steady since February 2025, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 2 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
6/23/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2024
  • 1 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/20/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/20/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/19/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/18/2025

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/13/2025HC WainwrightReiterated RatingBuy ➝ Buy$250.00 ➝ $250.00
4/1/2025William BlairReiterated RatingMarket Perform
3/18/2025HC WainwrightReiterated RatingBuy ➝ Buy$250.00 ➝ $250.00
2/20/2025HC WainwrightReiterated RatingBuy ➝ Buy$250.00 ➝ $250.00
12/17/2024HC WainwrightUpgradeStrong-Buy
11/13/2024William BlairReiterated RatingMarket Perform
6/3/2024William BlairReiterated RatingMarket Perform
2/27/2024William BlairReiterated RatingMarket Perform
8/8/2023Bank of AmericaDowngradeNeutral ➝ Underperform$100.00 ➝ $50.00
6/26/2023Stifel NicolausDowngradeBuy ➝ Hold
6/26/2023Bank of AmericaDowngradeBuy ➝ Neutral
6/26/2023Raymond James FinancialDowngradeOutperform ➝ Market Perform
6/26/2023William BlairDowngradeOutperform ➝ Market Perform
6/1/2023Stifel NicolausUpgradeHold ➝ Buy$575.00 ➝ $800.00
2/28/2023CowenBoost TargetMarket Perform$375.00 ➝ $625.00
2/21/2023The Goldman Sachs GroupBoost TargetSell$225.00 ➝ $400.00
1/30/2023William BlairUpgradeMarket Perform ➝ Outperform
1/26/2023Raymond James FinancialUpgradeMarket Perform ➝ Outperform$875.00
1/5/2023Bank of AmericaUpgradeNeutral ➝ Buy$450.00 ➝ $675.00
8/15/2022CowenBoost Target$350.00
5/24/2022The Goldman Sachs GroupLower TargetSell$225.00 ➝ $200.00
3/1/2022The Goldman Sachs GroupLower TargetSell$250.00 ➝ $225.00
9/22/2021The Goldman Sachs GroupDowngradeNeutral ➝ Sell$400.00 ➝ $275.00
8/20/2021Raymond James FinancialUpgradeUnderperform ➝ Market Perform
8/11/2021The Goldman Sachs GroupBoost TargetNeutral$400.00 ➝ $550.00
8/10/2021Leerink PartnersLower TargetPositive ➝ Outperform$875.00 ➝ $750.00
7/16/2021Leerink PartnersReiterated RatingOutperform$1,400.00 ➝ $875.00
7/16/2021CowenLower TargetMarket Perform$525.00 ➝ $400.00
7/16/2021MizuhoLower TargetNeutral$800.00 ➝ $450.00
7/16/2021Bank of AmericaDowngradeBuy ➝ Neutral$725.00
7/16/2021Stifel NicolausDowngradeBuy ➝ Hold$1,375.00 ➝ $725.00
6/28/2021MizuhoBoost TargetPositive ➝ Neutral$725.00 ➝ $800.00
4/13/2021HC WainwrightReiterated RatingBuy ➝ Neutral
4/13/2021MizuhoReiterated RatingBuy ➝ Neutral$725.00
4/7/2021JPMorgan Chase & Co.UpgradeNeutral
4/7/2021Leerink PartnersLower TargetOutperform$1,600.00 ➝ $1,400.00
4/7/2021Raymond James FinancialReiterated RatingSell
4/7/2021MizuhoDowngradeBuy ➝ Neutral$1,800.00 ➝ $725.00
4/7/2021HC WainwrightDowngradeBuy ➝ Neutral
3/31/2021Bank of AmericaUpgradeNeutral ➝ Buy$1,175.00
3/8/2021Jefferies Financial GroupReiterated RatingBuy ➝ Hold$1,875.00 ➝ $1,125.00
3/2/2021Leerink PartnersLower TargetOutperform$2,275.00 ➝ $1,600.00
3/2/2021Jefferies Financial GroupDowngradeBuy ➝ Hold$1,875.00 ➝ $1,125.00
2/1/2021HC WainwrightInitiated CoverageBuy$1,450.00
11/6/2020Leerink PartnersBoost TargetOutperform$2,250.00 ➝ $2,300.00
10/26/2020Raymond James FinancialInitiated CoverageUnderperform
9/8/2020Leerink PartnersBoost TargetOutperform$2,100.00 ➝ $2,250.00
8/7/2020Leerink PartnersBoost TargetOutperform$2,000.00 ➝ $2,100.00
(Data available from 6/18/2020 forward)

News Sentiment Rating

0.28 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/20/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/20/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/19/2025
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/18/2025
  • 2 very positive mentions
  • 16 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
3/20/2025
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/19/2025
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
5/19/2025
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/18/2025

Current Sentiment

  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
FibroGen logo
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Read More

Today's Range

Now: $5.16
Low: $5.16
High: $6.02

50 Day Range

MA: $7.64
Low: $5.88
High: $8.61

52 Week Range

Now: $5.16
Low: $4.50
High: $38.25

Volume

110,153 shs

Average Volume

79,281 shs

Market Capitalization

$20.85 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.83

Frequently Asked Questions

What sell-side analysts currently cover shares of FibroGen?

The following Wall Street analysts have issued research reports on FibroGen in the last year: HC Wainwright, Wall Street Zen, and William Blair.
View the latest analyst ratings for FGEN.

What is the current price target for FibroGen?

0 Wall Street analysts have set twelve-month price targets for FibroGen in the last year. Their average twelve-month price target is $250.00, suggesting a possible upside of 4,379.5%. HC Wainwright has the highest price target set, predicting FGEN will reach $250.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $250.00 for FibroGen in the next year.
View the latest price targets for FGEN.

What is the current consensus analyst rating for FibroGen?

FibroGen currently has 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for FGEN.

What other companies compete with FibroGen?

Other companies that are similar to FibroGen include Procaps Group, Corbus Pharmaceuticals, Exozymes, Caribou Biosciences and Tenaya Therapeutics. Learn More about companies similar to FibroGen.

How do I contact FibroGen's investor relations team?

FibroGen's physical mailing address is 409 ILLINOIS STREET, SAN FRANCISCO CA, 94158. The biopharmaceutical company's listed phone number is (415) 978-1200 and its investor relations email address is [email protected]. The official website for FibroGen is www.fibrogen.com. Learn More about contacing FibroGen investor relations.